A New Class of Drugs to treat Type 2 Diabetes:

More presentations from Dr.Naina Mohamed Pakkir Maideen

SGLT2 Inhibitors (Gliflozins):

©  Sodium-Glucose Linked Transporter 2 (SGLT2) inhibitors such as Dapagliflozin (Farxiga), Canagliflozin (Invokana) and Empagliflozin (Jardiance) are a new class of oral drugs available to treat type 2 diabetes mellitus (Type 2 DM).

©  Dapagliflozin is the first drug to be developed, but got FDA approval by 8^th Jan 2014.

©  Canagliflozin is the first drug to be approved by FDA which got the approval by 29^th Mar 2013.

©  Empagliflozin got the FDA approval by 1^st Aug 2014.

©  Gliflozins inhibit SGLT2 transoporter at Proximal Convoluted tubule and prevent the reabsorption of glucose which can lead to glycosuria and reduction of blood glucose levels.

©  Through glycosuria, SGLT2 inhibitors induce net calorie loss of approximately 200–300 kilocalories per day which can cause beneficial effect of weight loss.

©  SGLT2 inhibitors induced glycosuria, also cause dehydration which could lead to reduction of blood pressure.

©  Common adverse effects of SGLT2 inhibitors include urinary tract infections and female genital fungal infections might be caused by glycosuria.

©  Increased urination, rapid weight loss and tiredness may also be caused by glycosuria.

©  SGLT2 inhibitors induced hypotension can result in dizziness and/or fainting and a decline in renal function.

©  SGLT2 inhibitors should not be used in patients with Type 1 Diabetes, Diabetic ketoacidosis, Severe renal impairment, End stage renal disease and Dialysis patients.

©  The risk of Hypotensive reactions (Dizziness, fainting, etc.) possibly increased by the concomitant use of SGLT2 inhibitors and Diuretics.